iCo Therapeutics Inc. is a Vancouver-based biotechnology company engaged in reprofiling (redosing or reformulating) existing drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products, iCo-007, in Phase I for the treatment of diabetes related blindness, iCo-008, a product with Phase II clinical history to be developed for severe ocular allergies, and iCo-009, an oral reformulation of Amphotericin B for life threatening fungal infections. iCo-009 also represents a new drug delivery technology with the potential to reprofile other IV administered drugs to the oral route of administration.

iCo Therapeutics trades on the TSX-Venture exchange under the symbol “ICO”. www.icotherapeutics.com

CBC Interview with Dr. Kishor Wasan (3.86 MB)